VildagliptinA Review of its Use in Type 2 Diabetes Mellitus

被引：0
作者：
Gillian M. Keating
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2010年 / 70卷
关键词：
Metformin; Rosiglitazone; Pioglitazone; Acarbose; Sitagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vildagliptin (Galvus®, Jalra®, Xiliarx®) is an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor. In patients with type 2 diabetes mellitus, vildagliptin 50mg twice daily is indicated for use in combination with metformin or a thiazolidinedione, and vildagliptin 50mg once daily is indicated for use in combination with a sulfonylurea. A fixed-dose combination of vildagliptin/metformin (Eucreas®, Icandra®, Zomarist®) is also available. This article reviews the clinical efficacy and tolerability of vildagliptin in patients with type 2 diabetes, as well as summarizing its pharmacological properties.
引用
收藏
页码：2089 / 2112
页数：23
相关论文
共 250 条
  • [51] Collober C(2009)Absorption, metabolism, and excretion of [ Drug Metab Dispos 37 536-86
  • [52] Garber AJ(2007)C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans Eur J Clin Pharmacol 63 677-46
  • [53] Schweizer A(2008)The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin Br J Clin Pharmacol 65 338-49
  • [54] Baron MA(2009)The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers J Clin Pharmacol 49 39-95
  • [55] Rosenstock J(2010)Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers Int J Clin Pharmacol Ther 48 582-72
  • [56] Kim SW(2009)Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes Curr Med Res Opin 25 1265-64
  • [57] Baron MA(2008)Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes Int J Clin Pharmacol Ther 46 349-1004
  • [58] Garber AJ(2007)Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes J Clin Pharmacol 47 998-95
  • [59] Foley JE(2008)Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers J Clin Pharmacol 48 85-20
  • [60] Banerji MA(2007)Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects Curr Med Res Opin 23 2913-8
12345678910